Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

Prediction of Upstaged Ductal Carcinoma in situ Using Forced Labeling and Domain Adaptation.

Hou R, Mazurowski MA, Grimm LJ, Marks JR, King LM, Maley CC, Hwang ES, Lo JY.

IEEE Trans Biomed Eng. 2019 Sep 9. doi: 10.1109/TBME.2019.2940195. [Epub ahead of print]

PMID:
31502960
2.

Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression.

Hu Q, Ye Y, Chan LC, Li Y, Liang K, Lin A, Egranov SD, Zhang Y, Xia W, Gong J, Pan Y, Chatterjee SS, Yao J, Evans KW, Nguyen TK, Park PK, Liu J, Coarfa C, Donepudi SR, Putluri V, Putluri N, Sreekumar A, Ambati CR, Hawke DH, Marks JR, Gunaratne PH, Caudle AS, Sahin AA, Hortobagyi GN, Meric-Bernstam F, Chen L, Yu D, Hung MC, Curran MA, Han L, Lin C, Yang L.

Nat Immunol. 2019 Jul;20(7):835-851. doi: 10.1038/s41590-019-0400-7. Epub 2019 Jun 3.

PMID:
31160797
3.

Association of distant recurrence-free survival with algorithmically extracted MRI characteristics in breast cancer.

Mazurowski MA, Saha A, Harowicz MR, Cain EH, Marks JR, Marcom PK.

J Magn Reson Imaging. 2019 Jun;49(7):e231-e240. doi: 10.1002/jmri.26648. Epub 2019 Jan 22.

PMID:
30672045
4.

LncRNAs-directed PTEN enzymatic switch governs epithelial-mesenchymal transition.

Hu Q, Li C, Wang S, Li Y, Wen B, Zhang Y, Liang K, Yao J, Ye Y, Hsiao H, Nguyen TK, Park PK, Egranov SD, Hawke DH, Marks JR, Han L, Hung MC, Zhang B, Lin C, Yang L.

Cell Res. 2019 Apr;29(4):286-304. doi: 10.1038/s41422-018-0134-3. Epub 2019 Jan 10.

PMID:
30631154
5.

LncRNA CamK-A Regulates Ca2+-Signaling-Mediated Tumor Microenvironment Remodeling.

Sang LJ, Ju HQ, Liu GP, Tian T, Ma GL, Lu YX, Liu ZX, Pan RL, Li RH, Piao HL, Marks JR, Yang LJ, Yan Q, Wang W, Shao J, Zhou Y, Zhou T, Lin A.

Mol Cell. 2018 Nov 1;72(3):601. doi: 10.1016/j.molcel.2018.10.024. No abstract available.

PMID:
30388414
6.

Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set.

Cain EH, Saha A, Harowicz MR, Marks JR, Marcom PK, Mazurowski MA.

Breast Cancer Res Treat. 2019 Jan;173(2):455-463. doi: 10.1007/s10549-018-4990-9. Epub 2018 Oct 16.

PMID:
30328048
7.

Clinical effectiveness of the Manchester Glaucoma Enhanced Referral Scheme.

Gunn PJG, Marks JR, Konstantakopoulou E, Edgar DF, Lawrenson JG, Roberts SA, Spencer AF, Fenerty CH, Harper RA.

Br J Ophthalmol. 2019 Aug;103(8):1066-1071. doi: 10.1136/bjophthalmol-2018-312385. Epub 2018 Oct 11.

8.

LncRNA CamK-A Regulates Ca2+-Signaling-Mediated Tumor Microenvironment Remodeling.

Sang LJ, Ju HQ, Liu GP, Tian T, Ma GL, Lu YX, Liu ZX, Pan RL, Li RH, Piao HL, Marks JR, Yang LJ, Yan Q, Wang W, Shao J, Zhou Y, Zhou T, Lin A.

Mol Cell. 2018 Oct 4;72(1):71-83.e7. doi: 10.1016/j.molcel.2018.08.014. Epub 2018 Sep 13. Erratum in: Mol Cell. 2018 Nov 1;72(3):601.

PMID:
30220561
9.

Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival.

Saha A, Harowicz MR, Cain EH, Hall AH, Hwang ES, Marks JR, Marcom PK, Mazurowski MA.

Breast Cancer Res Treat. 2018 Nov;172(1):123-132. doi: 10.1007/s10549-018-4879-7. Epub 2018 Jul 10.

PMID:
29992418
10.

Expression of Long Noncoding RNA YIYA Promotes Glycolysis in Breast Cancer.

Xing Z, Zhang Y, Liang K, Yan L, Xiang Y, Li C, Hu Q, Jin F, Putluri V, Putluri N, Coarfa C, Sreekumar A, Park PK, Nguyen TK, Wang S, Zhou J, Zhou Y, Marks JR, Hawke DH, Hung MC, Yang L, Han L, Ying H, Lin C.

Cancer Res. 2018 Aug 15;78(16):4524-4532. doi: 10.1158/0008-5472.CAN-17-0385. Epub 2018 Jul 2.

11.

CircIRAK3 sponges miR-3607 to facilitate breast cancer metastasis.

Wu J, Jiang Z, Chen C, Hu Q, Fu Z, Chen J, Wang Z, Wang Q, Li A, Marks JR, Guo C, Chen Y, Zhou J, Yang L, Lin C, Wang S.

Cancer Lett. 2018 Aug 28;430:179-192. doi: 10.1016/j.canlet.2018.05.033. Epub 2018 May 25.

PMID:
29803789
12.

Acceptability and use of glaucoma virtual clinics in the UK: a national survey of clinical leads.

Gunn PJG, Marks JR, Au L, Waterman H, Spry PGD, Harper RA.

BMJ Open Ophthalmol. 2018 Feb 16;3(1):e000127. doi: 10.1136/bmjophth-2017-000127. eCollection 2018.

13.

Prediction of Occult Invasive Disease in Ductal Carcinoma in Situ Using Deep Learning Features.

Shi B, Grimm LJ, Mazurowski MA, Baker JA, Marks JR, King LM, Maley CC, Hwang ES, Lo JY.

J Am Coll Radiol. 2018 Mar;15(3 Pt B):527-534. doi: 10.1016/j.jacr.2017.11.036. Epub 2018 Feb 2.

14.

JAK2-binding long noncoding RNA promotes breast cancer brain metastasis.

Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, Yao J, Mangala LS, Li C, Yang W, Park PK, Hawke DH, Zhou J, Zhou Y, Xia W, Hung MC, Marks JR, Gallick GE, Lopez-Berestein G, Flores ER, Sood AK, Huang S, Yu D, Yang L, Lin C.

J Clin Invest. 2017 Dec 1;127(12):4498-4515. doi: 10.1172/JCI91553. Epub 2017 Nov 13.

15.

LncRNA wires up Hippo and Hedgehog signaling to reprogramme glucose metabolism.

Zheng X, Han H, Liu GP, Ma YX, Pan RL, Sang LJ, Li RH, Yang LJ, Marks JR, Wang W, Lin A.

EMBO J. 2017 Nov 15;36(22):3325-3335. doi: 10.15252/embj.201797609. Epub 2017 Sep 28.

16.

Glycosylation of KEAP1 links nutrient sensing to redox stress signaling.

Chen PH, Smith TJ, Wu J, Siesser PF, Bisnett BJ, Khan F, Hogue M, Soderblom E, Tang F, Marks JR, Major MB, Swarts BM, Boyce M, Chi JT.

EMBO J. 2017 Aug 1;36(15):2233-2250. doi: 10.15252/embj.201696113. Epub 2017 Jun 29.

17.

Nanoscale manipulation of membrane curvature for probing endocytosis in live cells.

Zhao W, Hanson L, Lou HY, Akamatsu M, Chowdary PD, Santoro F, Marks JR, Grassart A, Drubin DG, Cui Y, Cui B.

Nat Nanotechnol. 2017 Aug;12(8):750-756. doi: 10.1038/nnano.2017.98. Epub 2017 Jun 5.

18.

Can Occult Invasive Disease in Ductal Carcinoma In Situ Be Predicted Using Computer-extracted Mammographic Features?

Shi B, Grimm LJ, Mazurowski MA, Baker JA, Marks JR, King LM, Maley CC, Hwang ES, Lo JY.

Acad Radiol. 2017 Sep;24(9):1139-1147. doi: 10.1016/j.acra.2017.03.013. Epub 2017 May 11.

19.

The LINK-A lncRNA interacts with PtdIns(3,4,5)P3 to hyperactivate AKT and confer resistance to AKT inhibitors.

Lin A, Hu Q, Li C, Xing Z, Ma G, Wang C, Li J, Ye Y, Yao J, Liang K, Wang S, Park PK, Marks JR, Zhou Y, Zhou J, Hung MC, Liang H, Hu Z, Shen H, Hawke DH, Han L, Zhou Y, Lin C, Yang L.

Nat Cell Biol. 2017 Mar;19(3):238-251. doi: 10.1038/ncb3473. Epub 2017 Feb 20.

20.

Can algorithmically assessed MRI features predict which patients with a preoperative diagnosis of ductal carcinoma in situ are upstaged to invasive breast cancer?

Harowicz MR, Saha A, Grimm LJ, Marcom PK, Marks JR, Hwang ES, Mazurowski MA.

J Magn Reson Imaging. 2017 Nov;46(5):1332-1340. doi: 10.1002/jmri.25655. Epub 2017 Feb 9.

21.

Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.

Harowicz MR, Robinson TJ, Dinan MA, Saha A, Marks JR, Marcom PK, Mazurowski MA.

Breast Cancer Res Treat. 2017 Feb;162(1):1-10. doi: 10.1007/s10549-016-4093-4. Epub 2017 Jan 7.

22.

PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.

Southey MC, Goldgar DE, Winqvist R, Pylkäs K, Couch F, Tischkowitz M, Foulkes WD, Dennis J, Michailidou K, van Rensburg EJ, Heikkinen T, Nevanlinna H, Hopper JL, Dörk T, Claes KB, Reis-Filho J, Teo ZL, Radice P, Catucci I, Peterlongo P, Tsimiklis H, Odefrey FA, Dowty JG, Schmidt MK, Broeks A, Hogervorst FB, Verhoef S, Carpenter J, Clarke C, Scott RJ, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Peto J, Dos-Santos-Silva I, Fletcher O, Johnson N, Bolla MK, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Marme F, Burwinkel B, Yang R, Guénel P, Truong T, Menegaux F, Sanchez M, Bojesen S, Nielsen SF, Flyger H, Benitez J, Zamora MP, Perez JI, Menéndez P, Anton-Culver H, Neuhausen S, Ziogas A, Clarke CA, Brenner H, Arndt V, Stegmaier C, Brauch H, Brüning T, Ko YD, Muranen TA, Aittomäki K, Blomqvist C, Bogdanova NV, Antonenkova NN, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Spurdle AB, Investigators K; Australian Ovarian Cancer Study Group, Wauters E, Smeets D, Beuselinck B, Floris G, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Olson JE, Vachon C, Pankratz VS, McLean C, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Kristensen V, Alnæs GG, Zheng W, Hunter DJ, Lindstrom S, Hankinson SE, Kraft P, Andrulis I, Knight JA, Glendon G, Mulligan AM, Jukkola-Vuorinen A, Grip M, Kauppila S, Devilee P, Tollenaar RA, Seynaeve C, Hollestelle A, Garcia-Closas M, Figueroa J, Chanock SJ, Lissowska J, Czene K, Darabi H, Eriksson M, Eccles DM, Rafiq S, Tapper WJ, Gerty SM, Hooning MJ, Martens JW, Collée JM, Tilanus-Linthorst M, Hall P, Li J, Brand JS, Humphreys K, Cox A, Reed MW, Luccarini C, Baynes C, Dunning AM, Hamann U, Torres D, Ulmer HU, Rüdiger T, Jakubowska A, Lubinski J, Jaworska K, Durda K, Slager S, Toland AE, Ambrosone CB, Yannoukakos D, Swerdlow A, Ashworth A, Orr N, Jones M, González-Neira A, Pita G, Alonso MR, Álvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, Simard J, Dumont M, Soucy P, Eeles R, Muir K, Wiklund F, Gronberg H, Schleutker J, Nordestgaard BG, Weischer M, Travis RC, Neal D, Donovan JL, Hamdy FC, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Schaid DJ, Kelley JL, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Butterbach K, Park J, Kaneva R, Batra J, Teixeira MR, Kote-Jarai Z, Olama AA, Benlloch S, Renner SP, Hartmann A, Hein A, Ruebner M, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Lambretchs S, Doherty JA, Rossing MA, Nickels S, Eilber U, Wang-Gohrke S, Odunsi K, Sucheston-Campbell LE, Friel G, Lurie G, Killeen JL, Wilkens LR, Goodman MT, Runnebaum I, Hillemanns PA, Pelttari LM, Butzow R, Modugno F, Edwards RP, Ness RB, Moysich KB, du Bois A, Heitz F, Harter P, Kommoss S, Karlan BY, Walsh C, Lester J, Jensen A, Kjaer SK, Høgdall E, Peissel B, Bonanni B, Bernard L, Goode EL, Fridley BL, Vierkant RA, Cunningham JM, Larson MC, Fogarty ZC, Kalli KR, Liang D, Lu KH, Hildebrandt MA, Wu X, Levine DA, Dao F, Bisogna M, Berchuck A, Iversen ES, Marks JR, Akushevich L, Cramer DW, Schildkraut J, Terry KL, Poole EM, Stampfer M, Tworoger SS, Bandera EV, Orlow I, Olson SH, Bjorge L, Salvesen HB, van Altena AM, Aben KK, Kiemeney LA, Massuger LF, Pejovic T, Bean Y, Brooks-Wilson A, Kelemen LE, Cook LS, Le ND, Górski B, Gronwald J, Menkiszak J, Høgdall CK, Lundvall L, Nedergaard L, Engelholm SA, Dicks E, Tyrer J, Campbell I, McNeish I, Paul J, Siddiqui N, Glasspool R, Whittemore AS, Rothstein JH, McGuire V, Sieh W, Cai H, Shu XO, Teten RT, Sutphen R, McLaughlin JR, Narod SA, Phelan CM, Monteiro AN, Fenstermacher D, Lin HY, Permuth JB, Sellers TA, Chen YA, Tsai YY, Chen Z, Gentry-Maharaj A, Gayther SA, Ramus SJ, Menon U, Wu AH, Pearce CL, Van Den Berg D, Pike MC, Dansonka-Mieszkowska A, Plisiecka-Halasa J, Moes-Sosnowska J, Kupryjanczyk J, Pharoah PD, Song H, Winship I, Chenevix-Trench G, Giles GG, Tavtigian SV, Easton DF, Milne RL.

J Med Genet. 2016 Dec;53(12):800-811. doi: 10.1136/jmedgenet-2016-103839. Epub 2016 Sep 5.

23.

Effectiveness of an interprofessional workshop on pain management for medical and nursing students.

Erickson JM, Brashers V, Owen J, Marks JR, Thomas SM.

J Interprof Care. 2016 Jul;30(4):466-74. doi: 10.3109/13561820.2016.1159185. Epub 2016 Jun 6.

PMID:
27268513
24.

Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions.

Adams DL, Adams DK, Alpaugh RK, Cristofanilli M, Martin SS, Chumsri S, Tang CM, Marks JR.

Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1037-42. doi: 10.1158/1055-9965.EPI-15-1221. Epub 2016 May 17.

25.

Integrative analyses reveal signaling pathways underlying familial breast cancer susceptibility.

Piccolo SR, Hoffman LM, Conner T, Shrestha G, Cohen AL, Marks JR, Neumayer LA, Agarwal CA, Beckerle MC, Andrulis IL, Spira AE, Moos PJ, Buys SS, Johnson WE, Bild AH.

Mol Syst Biol. 2016 Mar 10;12(3):860. doi: 10.15252/msb.20156506.

26.

The LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancer.

Lin A, Li C, Xing Z, Hu Q, Liang K, Han L, Wang C, Hawke DH, Wang S, Zhang Y, Wei Y, Ma G, Park PK, Zhou J, Zhou Y, Hu Z, Zhou Y, Marks JR, Liang H, Hung MC, Lin C, Yang L.

Nat Cell Biol. 2016 Feb;18(2):213-24. doi: 10.1038/ncb3295. Epub 2016 Jan 11.

27.

Outcomes of Active Surveillance for Ductal Carcinoma in Situ: A Computational Risk Analysis.

Ryser MD, Worni M, Turner EL, Marks JR, Durrett R, Hwang ES.

J Natl Cancer Inst. 2015 Dec 17;108(5). pii: djv372. doi: 10.1093/jnci/djv372. Print 2016 May.

28.

Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer.

Lawrenson K, Iversen ES, Tyrer J, Weber RP, Concannon P, Hazelett DJ, Li Q, Marks JR, Berchuck A, Lee JM, Aben KK, Anton-Culver H, Antonenkova N; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group, Bandera EV, Bean Y, Beckmann MW, Bisogna M, Bjorge L, Bogdanova N, Brinton LA, Brooks-Wilson A, Bruinsma F, Butzow R, Campbell IG, Carty K, Chang-Claude J, Chenevix-Trench G, Chen A, Chen Z, Cook LS, Cramer DW, Cunningham JM, Cybulski C, Plisiecka-Halasa J, Dennis J, Dicks E, Doherty JA, Dörk T, du Bois A, Eccles D, Easton DT, Edwards RP, Eilber U, Ekici AB, Fasching PA, Fridley BL, Gao YT, Gentry-Maharaj A, Giles GG, Glasspool R, Goode EL, Goodman MT, Gronwald J, Harter P, Hasmad HN, Hein A, Heitz F, Hildebrandt MA, Hillemanns P, Hogdall E, Hogdall C, Hosono S, Jakubowska A, Paul J, Jensen A, Karlan BY, Kjaer SK, Kelemen LE, Kellar M, Kelley JL, Kiemeney LA, Krakstad C, Lambrechts D, Lambrechts S, Le ND, Lee AW, Cannioto R, Leminen A, Lester J, Levine DA, Liang D, Lissowska J, Lu K, Lubinski J, Lundvall L, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Nevanlinna H, McNeish I, Menon U, Modugno F, Moysich KB, Narod SA, Nedergaard L, Ness RB, Noor Azmi MA, Odunsi K, Olson SH, Orlow I, Orsulic S, Pearce CL, Pejovic T, Pelttari LM, Permuth-Wey J, Phelan CM, Pike MC, Poole EM, Ramus SJ, Risch HA, Rosen B, Rossing MA, Rothstein JH, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Budzilowska A, Sellers TA, Shu XO, Shvetsov YB, Siddiqui N, Sieh W, Song H, Southey MC, Sucheston L, Tangen IL, Teo SH, Terry KL, Thompson PJ, Timorek A, Tworoger SS, Van Nieuwenhuysen E, Vergote I, Vierkant RA, Wang-Gohrke S, Walsh C, Wentzensen N, Whittemore AS, Wicklund KG, Wilkens LR, Woo YL, Wu X, Wu AH, Yang H, Zheng W, Ziogas A, Coetzee GA, Freedman ML, Monteiro AN, Moes-Sosnowska J, Kupryjanczyk J, Pharoah PD, Gayther SA, Schildkraut JM.

Carcinogenesis. 2015 Nov;36(11):1341-53. doi: 10.1093/carcin/bgv138. Epub 2015 Sep 29.

29.

Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.

Elsarraj HS, Hong Y, Valdez KE, Michaels W, Hook M, Smith WP, Chien J, Herschkowitz JI, Troester MA, Beck M, Inciardi M, Gatewood J, May L, Cusick T, McGinness M, Ricci L, Fan F, Tawfik O, Marks JR, Knapp JR, Yeh HW, Thomas P, Carrasco DR, Fields TA, Godwin AK, Behbod F.

Breast Cancer Res. 2015 Sep 17;17:128. doi: 10.1186/s13058-015-0630-z.

30.

Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma.

Siamakpour-Reihani S, Owzar K, Jiang C, Turner T, Deng Y, Bean SM, Horton JK, Berchuck A, Marks JR, Dewhirst MW, Alvarez Secord A.

Gynecol Oncol. 2015 Oct;139(1):23-9. doi: 10.1016/j.ygyno.2015.08.001. Epub 2015 Aug 7.

31.

Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease.

Marks JR, Anderson KS, Engstrom P, Godwin AK, Esserman LJ, Longton G, Iversen ES, Mathew A, Patriotis C, Pepe MS.

Cancer Epidemiol Biomarkers Prev. 2015 Feb;24(2):435-41. doi: 10.1158/1055-9965.EPI-14-1178. Epub 2014 Dec 3.

32.

A joint analysis of metabolomics and genetics of breast cancer.

Tang X, Lin CC, Spasojevic I, Iversen ES, Chi JT, Marks JR.

Breast Cancer Res. 2014 Aug 5;16(4):415. doi: 10.1186/s13058-014-0415-9.

33.

Refining the role of BRCA1 in combating oxidative stress.

Marks JR.

Breast Cancer Res. 2013 Dec 5;15(6):320. doi: 10.1186/bcr3583.

34.

Molecular signatures of epithelial ovarian cancer: analysis of associations with tumor characteristics and epidemiologic risk factors.

Schildkraut JM, Iversen ES, Akushevich L, Whitaker R, Bentley RC, Berchuck A, Marks JR.

Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1709-21. doi: 10.1158/1055-9965.EPI-13-0192. Epub 2013 Aug 5.

35.

Oxidatively modified proteins as plasma biomarkers in breast cancer.

Jin H, Daly DS, Marks JR, Zangar RC.

Cancer Biomark. 2013;13(3):193-200. doi: 10.3233/CBM-130349.

36.

Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues.

Sfakianos GP, Iversen ES, Whitaker R, Akushevich L, Schildkraut JM, Murphy SK, Marks JR, Berchuck A.

Gynecol Oncol. 2013 Apr;129(1):159-64. doi: 10.1016/j.ygyno.2012.12.030. Epub 2012 Dec 26.

37.

Agreement between specially trained and accredited optometrists and glaucoma specialist consultant ophthalmologists in their management of glaucoma patients.

Marks JR, Harding AK, Harper RA, Williams E, Haque S, Spencer AF, Fenerty C.

Eye (Lond). 2012 Jun;26(6):853-61. doi: 10.1038/eye.2012.58. Epub 2012 Apr 13.

38.

Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers.

Lowery WJ, Schildkraut JM, Akushevich L, Bentley R, Marks JR, Huntsman D, Berchuck A.

Int J Gynecol Cancer. 2012 Jan;22(1):9-14. doi: 10.1097/IGC.0b013e318231f140.

39.

Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia.

Kung HN, Marks JR, Chi JT.

PLoS Genet. 2011 Aug;7(8):e1002229. doi: 10.1371/journal.pgen.1002229. Epub 2011 Aug 11.

40.

Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes.

Gatza ML, Kung HN, Blackwell KL, Dewhirst MW, Marks JR, Chi JT.

Breast Cancer Res. 2011 Jun 7;13(3):R62. doi: 10.1186/bcr2899.

41.

Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.

Gonzalez RM, Daly DS, Tan R, Marks JR, Zangar RC.

Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1543-51. doi: 10.1158/1055-9965.EPI-10-1248. Epub 2011 May 17.

42.

Spontaneous membrane-translocating peptides by orthogonal high-throughput screening.

Marks JR, Placone J, Hristova K, Wimley WC.

J Am Chem Soc. 2011 Jun 15;133(23):8995-9004. doi: 10.1021/ja2017416. Epub 2011 May 19.

43.

The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy.

Wardell SE, Marks JR, McDonnell DP.

Biochem Pharmacol. 2011 Jul 15;82(2):122-30. doi: 10.1016/j.bcp.2011.03.031. Epub 2011 Apr 9.

44.

Regulator of G protein signaling 5 is highly expressed in parathyroid tumors and inhibits signaling by the calcium-sensing receptor.

Koh J, Dar M, Untch BR, Dixit D, Shi Y, Yang Z, Adam MA, Dressman H, Wang X, Gesty-Palmer D, Marks JR, Spurney R, Druey KM, Olson JA Jr.

Mol Endocrinol. 2011 May;25(5):867-76. doi: 10.1210/me.2010-0277. Epub 2011 Mar 10.

45.

Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction.

Havrilesky LJ, Sanders GD, Kulasingam S, Chino JP, Berchuck A, Marks JR, Myers ER.

Cancer. 2011 Feb 1;117(3):545-53. doi: 10.1002/cncr.25624. Epub 2010 Dec 13.

46.

Severe obesity is associated with symptomatic presentation, higher parathyroid hormone levels, and increased gland weight in primary hyperparathyroidism.

Adam MA, Untch BR, Danko ME, Stinnett S, Dixit D, Koh J, Marks JR, Olson JA Jr.

J Clin Endocrinol Metab. 2010 Nov;95(11):4917-24. doi: 10.1210/jc.2010-0666. Epub 2010 Aug 4.

47.

Expression signatures of TP53 mutations in serous ovarian cancers.

Bernardini MQ, Baba T, Lee PS, Barnett JC, Sfakianos GP, Secord AA, Murphy SK, Iversen E, Marks JR, Berchuck A.

BMC Cancer. 2010 May 26;10:237. doi: 10.1186/1471-2407-10-237.

48.

Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients.

Liggett TE, Melnikov AA, Marks JR, Levenson VV.

Int J Cancer. 2011 Jan 15;128(2):492-9. doi: 10.1002/ijc.25363. Epub 2010 Apr 5.

49.

Improved staging in node-positive breast cancer patients using lymph node ratio: results in 1,788 patients with long-term follow-up.

Danko ME, Bennett KM, Zhai J, Marks JR, Olson JA Jr.

J Am Coll Surg. 2010 May;210(5):797-805.e1, 805-7. doi: 10.1016/j.jamcollsurg.2010.02.045.

PMID:
20421053
50.

Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer.

Schildkraut JM, Iversen ES, Wilson MA, Clyde MA, Moorman PG, Palmieri RT, Whitaker R, Bentley RC, Marks JR, Berchuck A.

PLoS One. 2010 Apr 8;5(4):e10061. doi: 10.1371/journal.pone.0010061.

Supplemental Content

Loading ...
Support Center